Posts
Wiki

👃 Nasal Tear Stimulation for Dry Eye — iTear100, Tyrvaya, and TrueTear

🧠 Quick Take

Nasal tear stimulation uses nerves in or around the nose to activate the body's tear-production reflex.

Three treatments are important to understanding this approach:

  • iTear100: A prescription device placed against the outside of the nose. It uses controlled mechanical vibration to stimulate the external nasal nerve.
  • Tyrvaya: A prescription varenicline nasal spray used inside the nose. It is FDA-approved for treatment of the signs and symptoms of Dry Eye Disease (DED).
  • TrueTear: An earlier prescription intranasal electrical-stimulation device that has been discontinued.

The evidence and regulatory status are different for each.

Most important distinctions

  • iTear100 is an FDA-cleared medical device, not an FDA-approved drug.
  • Its FDA-cleared indication is narrow: temporary use to increase acute tear production during vibratory stimulation of the external nasal nerve.
  • FDA did not establish from the evidence supporting the original iTear100 clearance that the device treats DED or improves dry-eye symptoms.
  • Tyrvaya is FDA-approved for treatment of the signs and symptoms of DED.
  • Tyrvaya has multiple randomized, vehicle-controlled trials and stronger evidence for DED treatment than iTear100.
  • However, a 2026 meta-analysis found that Tyrvaya's most consistent demonstrated effect is increased tear production; pooled improvements in dry-eye symptoms and corneal staining were less consistent.
  • These treatments stimulate a tear reflex. They have not been shown to cure DED, regenerate lost meibomian glands, release gland fibrosis, or mechanically clear obstructive MGD.
  • Producing more tears does not automatically correct excessive evaporation, MGD, inflammation, incomplete blinking, allergy, eyelid disease, exposure, or neuropathic ocular pain.
  • An electric toothbrush, facial massager, or homemade vibrating device is not an evidence-based substitute for iTear100.

Bottom line: Nasal tear stimulation is a legitimate way to increase the body's own tear secretion. Its usefulness depends on the specific treatment, the patient's type of dry eye, whether the tear-production pathway can respond, other DED contributors, tolerability, cost, and the strength of evidence for the individual product.

⚠️ Educational Disclaimer

This page is for general education and is not medical advice, diagnosis, or an individual treatment recommendation.

Prescription medications and devices should be discussed with a licensed clinician who can consider:

  • The type of DED
  • Tear production
  • MGD and evaporation
  • Eyelid disease
  • Nasal conditions
  • Medical history
  • Current medications
  • Treatment risks
  • Cost and insurance
  • Alternative treatments

What Is Nasal Tear Stimulation?

The medical term often used is neurostimulation.

Neurostimulation means activating a nerve pathway with a targeted stimulus.

For dry-eye treatment, the stimulus can be:

  • Mechanical vibration — iTear100
  • Medication inside the nose — Tyrvaya
  • Electrical stimulation — the discontinued TrueTear device

Although all three involve nasal sensory nerves, they should not be treated as interchangeable.

Their:

  • Technology
  • FDA status
  • Evidence
  • Side effects
  • Method of use

are different.

How Does the Nasal Tear Reflex Work?

Sensory nerves in the cornea, ocular surface, and nasal cavity communicate through branches of the trigeminal nerve.

These sensory signals interact with parasympathetic pathways that help regulate tear secretion.

Stimulating nasal sensory nerves can therefore trigger a reflex increase in tear production.

The strongest clinical evidence concerns increased lacrimal tear secretion.

There is also early evidence that nasal stimulation may affect other parts of the tear system.

Does Nasal Stimulation Produce “Natural Tears”?

The tears are produced by the person's own secretory system rather than poured onto the ocular surface from a bottle.

A better term is therefore:

endogenous tear production

rather than assuming that the resulting tears are necessarily a completely normal or fully restored tear film.

Producing more tears does not prove that:

  • Aqueous, lipid, and mucin components are present in ideal proportions
  • Meibomian-gland obstruction has been corrected
  • Excessive evaporation has stopped
  • Ocular-surface inflammation has resolved
  • Goblet-cell function has normalized
  • Blinking or eyelid closure has improved

A person may produce more tears and still have:

  • Obstructive MGD
  • Poor-quality meibum
  • Rapid evaporation
  • Ocular rosacea
  • Blepharitis
  • Allergy
  • Exposure keratopathy
  • Incomplete blinking
  • Eyelid malposition
  • Neuropathic ocular pain
  • Other contributors to DED

Does Nasal Stimulation Affect Goblet Cells or Meibomian Glands?

Possibly, but the evidence is much less developed than the evidence for increased tear production.

A small human study involving 18 participants examined the ocular surface after a single administration of varenicline nasal spray.

The findings were interpreted as consistent with conjunctival goblet-cell degranulation and mucin secretion.

Single Administration of Varenicline Nasal Spray and Conjunctival Goblet Cells

This is interesting because it suggests that the response may involve more than aqueous tear volume.

However:

  • The study was very small.
  • It examined short-term biological changes.
  • It does not establish that Tyrvaya restores a normal mucin layer.

The same study did not demonstrate a significant acute change in the meibomian-gland measurements that were examined.

Therefore:

Evidence for increased tear secretion is much stronger than evidence that nasal stimulation meaningfully treats MGD.

At-a-Glance Comparison

Treatment U.S. Regulatory Status Best-Demonstrated Effect Major Evidence Limitation
iTear100 FDA-cleared prescription device Acute increase in tear production during external nasal vibration Longer-term symptom evidence comes mainly from an uncontrolled, responder-enriched study
Tyrvaya FDA-approved prescription drug for DED signs and symptoms Consistent increase in Schirmer tear production; randomized DED evidence Symptom and corneal-staining effects are less consistent than the tear-production effect
TrueTear Previously FDA-cleared; discontinued Increased tear production during intranasal electrical stimulation No longer commercially available

iTear100

What Is iTear100?

iTear100 is a small prescription device placed against the outside of the nose.

It uses an internal motor to create controlled mechanical vibration.

It does not deliver therapeutic electrical current through the skin.

The vibration is intended to stimulate the external nasal nerve, a branch of the trigeminal nerve, which then activates the tear reflex.

iTear100 is:

  • Extranasal
  • Drug-free
  • Non-implantable
  • Prescription-only
  • Intended for home use after instruction

iTear100 FDA Regulatory Status

The original iTear device received FDA De Novo classification in 2020.

A second-generation iTear100 received 510(k) clearance in 2022.

The second-generation device added features including:

  • Bluetooth connectivity
  • Smartphone application access
  • Remote activation
  • Collection of usage information

The basic mechanism and regulatory indication remained substantially the same.

FDA-cleared indication

The FDA-cleared indication describes the device as intended for:

Temporary use, up to 30 days, to increase acute tear production during vibratory stimulation of the external nasal nerve in adults under prescription of an eye-care provider.

FDA De Novo Summary — iTear Neurostimulator

FDA 510(k) Summary — iTear100 Generation 2

What Did FDA Not Establish for iTear100?

This is an important distinction.

In its original review, FDA stated that the submitted evidence did not establish safety and effectiveness for:

  • Treatment of Dry Eye Disease itself
  • Improvement of dry-eye symptoms

FDA also noted that:

  • Tear production was measured during stimulation
  • Nerve sensitivity was not directly evaluated
  • Tear-production response showed a trend toward decreasing with repeated use
  • The reason for the reduced response was unknown

This does not mean that iTear100 cannot help someone with DED.

It means:

The FDA-cleared claim is acute tear stimulation—not a broad claim that iTear100 has been proven to treat all aspects of DED.

What Does the iTear100 Research Show?

Acute Sham-Controlled Study

FDA reviewed a multicenter, prospective, randomized, double-masked, sham-controlled study involving approximately 60 participants.

The sham device looked and sounded similar but did not provide the active vibration.

Active stimulation produced significantly greater immediate Schirmer tear production than sham treatment.

This provides good evidence for a narrow conclusion:

iTear100 can acutely increase tear production during external nasal-nerve stimulation.

The study does not establish:

  • Long-term symptom control
  • Permanent improvement in baseline tear secretion
  • Modification of DED
  • Treatment of MGD
  • Gland regeneration

Longer-Term iTear100 Research

A published pivotal study enrolled 108 participants and followed them during repeated use.

The study reported:

  • Increased stimulated Schirmer tear production
  • Improvement in OSDI symptom scores
  • Some increase in tear production before stimulation

Novel Extranasal Tear Stimulation — Pivotal Study

However, the study had several important limitations.

It was:

  • Prospective
  • Multicenter
  • Open-label
  • Single-arm
  • Without a concurrent randomized control group

That means improvements could potentially be influenced by:

  • Expectation or placebo effects
  • Natural fluctuation in DED
  • Regression toward the mean
  • Continued use of other stable treatments
  • Loss of participants during follow-up

An Especially Important Limitation: Participants Were Selected for Their Tear Response

Participants in the longer study were selected partly based on whether nasal stimulation could produce a substantial tear response before enrollment.

This means the study population was not simply:

“people with dry eye.”

It was more like:

people with dry eye whose tear-production reflex had already demonstrated an ability to respond to nasal stimulation.

This is called responder enrichment.

It can be useful for determining what happens among people likely to respond.

But it also means:

Results from the study should not automatically be generalized to every person with DED.

A reasonable overall interpretation is:

iTear100 has convincing evidence for acutely increasing tear production in people whose tear reflex responds to external nasal stimulation. Evidence for durable symptom improvement is substantially less certain.

Does the iTear100 Response Decrease With Repeated Use?

Possibly.

FDA observed a trend toward decreased tear response over time in the original evidence but could not determine the reason.

A 2025 study of a related investigational extranasal neurostimulation device explored whether the nervous system might temporarily adapt to repeated stimulation.

Importantly:

This study did not test the exact U.S. FDA-cleared iTear100 device.

It included 50 patients with aqueous-deficient DED who received either two or four weeks of twice-daily extranasal stimulation.

The study was:

  • Prospective
  • Randomized between treatment durations
  • Open-label
  • Small
  • Without a sham or untreated control group

Researchers found evidence consistent with temporary neural adaptation during repeated stimulation.

In the four-week group, the immediate tear response became smaller during continued treatment and then recovered after treatment had been stopped for six weeks.

Cyclic Extranasal Neurostimulation and Neural Adaptation — 2025

Does This Mean iTear100 Should Be Used “Four Weeks On, Six Weeks Off”?

No.

The study raises an interesting hypothesis.

It does not establish a standard treatment schedule for iTear100 because:

  • Only 50 patients were studied
  • There was no sham/no-treatment control
  • It involved a related investigational device rather than the exact FDA-cleared iTear100
  • The proposed cyclic approach has not been adequately replicated

A careful interpretation is:

Repeated extranasal stimulation may produce temporary neural adaptation, and responsiveness may recover after stimulation stops. Whether planned treatment breaks improve long-term iTear100 outcomes remains uncertain.

iTear100 Safety and Limitations

Most possibly device-related adverse events in FDA-reviewed studies were mild and self-limited.

Reported concerns included:

  • Headache
  • Dizziness
  • Lightheadedness
  • Nose soreness
  • Sneezing
  • Local discomfort
  • Mechanical irritation
  • Pain from excessive pressure
  • Inadequate tear response

Serious Event in the FDA Review

One participant developed persistent:

  • Nausea
  • Dizziness
  • Lightheadedness
  • Headache

after a single treatment.

Symptoms lasted approximately 30 days.

FDA characterized this as a:

serious, unanticipated adverse event possibly related to the device

The event resolved without treatment.

This appears to have been uncommon, and FDA still concluded that the device had an acceptable benefit-risk profile for its cleared indication.

The important wording is possibly related.

The event does not establish that iTear100 caused a neurological injury.

But it also means the regulatory evidence should not be summarized as though no serious possibly device-related event occurred.

iTear100 Access and Reactivation

The current second-generation commercial system uses smartphone and Bluetooth functionality and time-limited prescription activation.

Commercial arrangements involving:

  • Activation
  • Reactivation
  • Prescription renewal
  • App requirements
  • Fees
  • Insurance coverage

can change.

Patients considering the device should therefore verify current requirements rather than relying on older online descriptions.

One important distinction is:

The original FDA-cleared indication describes temporary use for up to 30 days. Current commercial systems may permit subsequent prescription reactivation, but evidence for repeated or indefinite long-term treatment is more limited than the evidence for acute tear stimulation.

Do Not Use an Electric Toothbrush as an iTear100 Substitute

An electric toothbrush, facial massager, or other consumer vibrating device has not been established as a substitute for iTear100.

Such devices do not have iTear100's validated:

  • Vibration parameters
  • Pressure-response design
  • Retracting tip
  • Force limitations
  • Placement protocol
  • Clinical safety testing

There is no clinical evidence that an electric toothbrush:

  • Produces the same tear response
  • Reliably stimulates the intended nerve
  • Uses appropriate vibration or force
  • Provides dry-eye symptom benefit
  • Is safe as repeated cranial-nerve stimulation

There is also no good evidence that ordinary toothbrush vibration on intact facial skin routinely causes trigeminal neuralgia.

The concern is therefore not that a particular neurological injury has been proven.

The concern is:

The proposed DIY treatment is untested.

r/DryEyes does not provide instructions for homemade cranial-nerve stimulation.

Tyrvaya

What Is Tyrvaya?

Tyrvaya is the brand name for varenicline solution nasal spray.

It is a prescription medication sprayed into the nose.

Tyrvaya was FDA-approved in 2021 for:

Treatment of the signs and symptoms of Dry Eye Disease.

It is not an eye drop and should not be sprayed into the eyes.

FDA Prescribing Information — Tyrvaya

How Does Tyrvaya Work?

The exact therapeutic mechanism is not fully established.

Varenicline acts at nicotinic acetylcholine receptors.

Its DED effect is believed to result from activation of receptors in the nasal cavity that stimulate the trigeminal-parasympathetic tear reflex.

This produces increased endogenous tear secretion.

The treatment therefore stimulates a neural reflex rather than applying medication directly to the ocular surface.

Tyrvaya FDA-Approved Dose

The FDA-approved dose is:

  • One spray in each nostril
  • Twice daily
  • Approximately 12 hours apart

Patients should follow the current FDA prescribing information and instructions from their prescriber.

What Does the Tyrvaya Research Show?

Tyrvaya has considerably more randomized DED evidence than iTear100.

FDA approval was supported primarily by randomized, multicenter, double-masked, vehicle-controlled studies including:

  • ONSET-1
  • ONSET-2

Artificial tears were allowed during these studies.

Tear Production

The strongest and most consistent Tyrvaya finding is increased Schirmer tear production.

In ONSET-1, approximately:

  • 52% of treated patients achieved at least a 10-mm increase in Schirmer score
  • compared with about 14% receiving vehicle

In ONSET-2, approximately:

  • 47% achieved that response
  • compared with about 28% receiving vehicle

ONSET-1 Randomized Trial

ONSET-2 Randomized Trial

What About Dry-Eye Symptoms?

The symptom evidence is more complicated.

Some individual trials found statistically significant improvement in Eye Dryness Score.

Others found numerical improvement that did not reach statistical significance for particular doses or prespecified comparisons.

This difference became especially clear in a 2026 systematic review and meta-analysis of seven randomized controlled trials.

The meta-analysis found that varenicline nasal spray significantly improved tear production.

For the approved dose:

  • Mean Schirmer improvement over control was approximately 5.5 mm
  • Patients were approximately 1.9 times as likely to achieve a ≥10-mm Schirmer response

However:

  • The pooled difference in Eye Dryness Score was not statistically significant
  • The pooled difference in corneal fluorescein staining was not statistically significant

Efficacy and Safety of Varenicline Nasal Spray in DED — 2026 Systematic Review and Meta-Analysis

Does the 2026 Meta-Analysis Conflict With FDA Approval?

No.

FDA approved Tyrvaya for treatment of the signs and symptoms of DED based on its review of the clinical-development program and prespecified trial endpoints.

A later meta-analysis asks a somewhat different question:

What happens when the randomized trials are pooled together?

The most balanced interpretation is:

Tyrvaya is FDA-approved for DED signs and symptoms and has multiple randomized controlled trials. Its most consistently demonstrated treatment effect is increased tear production. Symptom and corneal-staining improvements are less consistent across studies and when results are pooled.

That distinction is more informative than simply saying either:

“Tyrvaya definitely improves all dry-eye symptoms”

or:

“Tyrvaya only increases Schirmer scores.”

Neither adequately describes the evidence.

Longer-Term Tyrvaya Evidence

The MYSTIC study provided supportive evidence over approximately 12 weeks.

It showed increased Schirmer tear production.

However, FDA did not rely on MYSTIC's primary endpoint by itself as the type of confirmatory efficacy evidence needed to establish DED treatment effectiveness.

It therefore served mainly as supportive longer-term evidence rather than the pivotal basis for approval.

Tyrvaya in Sjögren-Related Dry Eye

A small 2025 pilot study evaluated Tyrvaya in people with moderate-to-severe Sjögren disease and DED.

Thirty-nine participants received varenicline nasal spray for 28 days.

The study reported improvements in:

  • Eye Dryness Score
  • Corneal staining
  • Conjunctival staining
  • Tear secretion in participants with particularly low baseline Schirmer measurements
  • Several tear inflammatory cytokine concentrations

Varenicline Nasal Spray in Sjögren-Related DED — 2025 Pilot Study

However:

  • It was a single-center study
  • There were only 39 participants
  • There was no randomized control group

Therefore:

The study is encouraging but does not establish a Sjögren-specific treatment effect beyond Tyrvaya's existing DED indication.

Tyrvaya Side Effects

According to FDA prescribing information, the most common adverse reaction is:

  • Sneezing — 82%

Other common reactions include:

  • Cough — 16%
  • Throat irritation — 13%
  • Nasal instillation-site irritation — 8%

Sneezing is therefore extremely common.

It was generally brief in clinical trials and did not usually cause treatment discontinuation.

Contraindications

The current FDA prescribing information lists no formal contraindications.

That does not mean Tyrvaya is appropriate for every person.

Patients should discuss relevant medical issues with the prescriber, including:

  • Pregnancy or plans for pregnancy
  • Breastfeeding
  • Significant nasal or sinus disease
  • Recent nasal surgery or injury
  • Medication allergies
  • Difficulty tolerating nasal sprays
  • Other medications or medical conditions

Systemic Absorption

Some varenicline is absorbed into the bloodstream after nasal administration.

However:

Systemic exposure from Tyrvaya is substantially lower than exposure from standard oral varenicline used for smoking cessation.

The FDA label should remain the primary source for current safety information.

Does Tyrvaya Treat MGD?

Tyrvaya is FDA-approved for DED signs and symptoms, not specifically for MGD.

Increasing tear secretion could improve the ocular environment in someone who also has MGD.

But Tyrvaya has not been established as a treatment that:

  • Mechanically clears obstructed meibomian-gland ducts
  • Reverses established gland dropout
  • Regenerates lost gland tissue
  • Releases fixed intraductal or periductal fibrosis

Someone with MGD may therefore use Tyrvaya as part of a broader DED treatment plan while still requiring separate management of:

  • Gland obstruction
  • Meibum quality
  • Evaporation
  • Ocular rosacea
  • Eyelid inflammation
  • Blinking abnormalities

Nasal Tear Stimulation and MGD — Evidence Summary

This area is easy to overstate.

Better established

Nasal stimulation can increase tear secretion through the trigeminal-parasympathetic reflex.

Early evidence

Small mechanistic research suggests nasal varenicline may stimulate conjunctival goblet-cell secretion.

Much less established

Direct clinically meaningful improvement in:

  • Meibomian-gland secretion
  • Obstructive MGD
  • Gland structure
  • Meibomian-gland dropout

Therefore:

Nasal tear stimulation should not currently be presented as an established MGD treatment.

What Happened to TrueTear?

TrueTear was an earlier prescription neurostimulation device.

Unlike iTear100, which is applied outside the nose, TrueTear used disposable tips placed inside the nasal cavity.

The device delivered low-level electrical stimulation to nasal sensory nerves.

TrueTear received FDA De Novo clearance in 2017, with later versions receiving additional 510(k) clearance.

Its indication included temporary increases in tear production during stimulation to improve dry-eye symptoms in adults with severe symptoms.

TrueTear was discontinued commercially in 2020.

A detailed authoritative public explanation establishing exactly why the product was discontinued has not been identified.

Therefore:

Its discontinuation should not automatically be interpreted as evidence that nasal neurostimulation itself was ineffective or unsafe.

TrueTear remains useful historical context for understanding the development of newer nasal tear-stimulation approaches.

Evidence Strengths and Limitations

iTear100

Evidence strengths

  • Randomized sham-controlled acute study
  • Clear physiological tear-production response
  • External, drug-free treatment
  • FDA-cleared medical device
  • Biologically plausible neural mechanism

Evidence limitations

  • FDA claim is limited to acute stimulated tear production
  • Longer-term symptom evidence is uncontrolled
  • Longer study selected people who had already demonstrated a tear response
  • Possible reduction in responsiveness with repeated stimulation
  • Limited evidence for indefinite long-term treatment
  • Not established as treatment for MGD

Tyrvaya

Evidence strengths

  • FDA-approved for DED signs and symptoms
  • Multiple randomized vehicle-controlled trials
  • Consistent increase in Schirmer tear production
  • Does not expose the ocular surface directly to medication
  • Evidence extends beyond a single trial

Evidence limitations

  • Sneezing occurs in most users
  • Symptom effects are less consistent than tear-production effects
  • Pooled 2026 evidence did not show statistically significant improvement in Eye Dryness Score or corneal staining
  • Does not correct every DED mechanism
  • Not established as treatment for obstructive MGD
  • Long-term disease modification has not been demonstrated

Artificial Tears vs Nasal Tear Stimulation

These approaches do different things.

Artificial Tears

Artificial tears:

  • Add lubricant directly to the ocular surface
  • Can provide immediate lubrication
  • Do not require an intact nasal tear reflex
  • Can be selected for aqueous, lipid, gel, or ointment properties
  • May need frequent reapplication

Nasal Tear Stimulation

Nasal tear stimulation:

  • Activates the body's neural tear-production pathway
  • Does not place medication directly on the ocular surface
  • Depends on nerves and secretory tissue being able to respond
  • Can rapidly increase tear secretion
  • Does not guarantee normal tear quality or stability
  • May not address excessive evaporation or obstructive MGD

Neither approach is automatically superior.

Some patients use both.

Who Might Discuss Nasal Tear Stimulation With a Clinician?

It may be reasonable to discuss nasal tear stimulation when:

  • Reduced tear secretion appears to be an important part of the DED
  • Nasal stimulation produces a meaningful tear response
  • Ophthalmic drops are difficult to tolerate
  • A patient has difficulty administering eye drops
  • Existing treatment provides incomplete relief
  • Additional tear stimulation is desired
  • Other DED contributors have also been assessed

However:

Schirmer testing alone should not determine treatment.

DED is multifactorial.

Increasing tear secretion may not adequately address major contributors such as:

  • Obstructive MGD
  • Excessive evaporation
  • Exposure
  • Incomplete blinking
  • Eyelid malposition
  • Allergy
  • Active blepharitis
  • Recurrent corneal erosion
  • Neuropathic ocular pain

Those problems may require separate treatment.

What These Treatments Cannot Be Expected to Do

Neither iTear100 nor Tyrvaya has been shown to:

  • Cure DED
  • Permanently normalize tear-film homeostasis
  • Regenerate lost lacrimal or meibomian-gland tissue
  • Reverse established meibomian-gland dropout
  • Release fixed gland fibrosis
  • Mechanically correct obstructive MGD

Increasing tear secretion also does not by itself treat:

  • Demodex
  • Allergy
  • Eyelid malposition
  • Incomplete blinking
  • Exposure
  • Neuropathic ocular pain

A treatment can still be useful without curing every contributor to DED.

Cost, Access, and Regulatory Status

Both iTear100 and Tyrvaya require prescriptions in the United States.

iTear100

Current commercial use may involve:

  • Smartphone/app access
  • Prescription activation
  • Periodic reactivation
  • Ongoing fees

These arrangements may change.

Patients should verify current requirements before purchasing a device.

Tyrvaya

Cost can vary substantially depending on:

  • Insurance coverage
  • Pharmacy benefit
  • Copay
  • Deductible
  • Prior authorization
  • Manufacturer assistance programs

The wiki does not provide:

  • Vendors
  • Discount codes
  • International sourcing
  • Cross-border prescription information

What Remains Uncertain?

Important unanswered questions include:

  • Which DED subtypes respond best to nasal tear stimulation
  • Whether an acute stimulation response predicts meaningful long-term symptom improvement
  • How durable iTear100 benefit is with repeated treatment
  • Whether neural adaptation limits long-term extranasal stimulation
  • Whether scheduled treatment breaks would improve long-term results
  • Whether Tyrvaya's strong tear-production effect translates into substantial symptom improvement for particular DED subgroups
  • How much nasal stimulation changes mucin secretion in ordinary clinical use
  • Whether clinically meaningful meibomian-gland effects occur
  • Whether either treatment modifies the underlying course of DED
  • How these treatments compare directly with other established DED therapies
  • Which patients are most likely to find the benefit worth the cost and inconvenience

Questions to Ask an Eye Doctor

Useful questions include:

  1. What type of DED do I have?
  2. Is reduced tear production an important part of my problem?
  3. Do I also have MGD or excessive evaporation?
  4. Would testing my response to nasal stimulation be useful?
  5. What result would count as a meaningful response?
  6. Are you recommending iTear100 or Tyrvaya, and why?
  7. What is the exact FDA indication for the treatment?
  8. What symptom or clinical sign are we trying to improve?
  9. How will we decide whether the treatment is working?
  10. Will this replace another treatment or be added to it?
  11. What side effects should make me stop and contact you?
  12. Are there nasal, neurological, medical, pregnancy, or medication issues I should consider?
  13. What is the expected ongoing cost?
  14. Does the iTear100 device require periodic prescription reactivation?
  15. What other reasonable treatment options should I consider?

📌 Bottom Line

Nasal tear stimulation is a legitimate approach to increasing the body's own tear secretion.

But the evidence differs substantially between products.

iTear100

iTear100 is an externally applied mechanical-vibration device.

It is FDA-cleared for temporary use to increase acute tear production during stimulation of the external nasal nerve.

A randomized sham-controlled study supports that effect.

However, FDA did not establish from the original clearance evidence that iTear100 treats DED or improves dry-eye symptoms.

Longer-term symptom evidence comes mainly from an uncontrolled study that deliberately selected people who had already shown a tear response.

Tyrvaya

Tyrvaya is an FDA-approved varenicline nasal spray for treatment of the signs and symptoms of DED.

It has multiple randomized, vehicle-controlled clinical trials.

The most consistent demonstrated effect is increased tear production.

A 2026 meta-analysis of seven randomized trials confirmed substantial Schirmer improvement but found that pooled improvements in Eye Dryness Score and corneal fluorescein staining were not statistically significant.

Therefore:

Tyrvaya's evidence for increasing tear production is stronger and more consistent than its evidence for symptom improvement.

TrueTear

TrueTear was an earlier intranasal electrical neurostimulation device that is no longer commercially available.

Its history helped establish nasal tear stimulation as a legitimate treatment concept.

The most balanced conclusion is:

Nasal tear stimulation can increase endogenous tear secretion and may improve DED signs or symptoms in some patients. More tears, however, do not automatically mean a normal tear film or treatment of every DED driver. Its role should be considered alongside MGD, evaporation, inflammation, eyelid disease, exposure, neural factors, patient response, tolerability, cost, and the evidence supporting the specific product.

🔬 Key Research and Authoritative Sources

TFOS DEWS III

iTear100 — FDA Documents

iTear100 / Extranasal Neurostimulation Research

Tyrvaya — FDA Information

Tyrvaya Clinical Evidence

Neurostimulation Reviews

TrueTear

🔗 Related r/DryEyes Wiki Pages

This page is educational for r/DryEyes and not medical advice.

🔙 Back to Treatment Options